Factors Associated with Altered Pharmacokinetics in Substance Users and Non-Substance Users Receiving Lopinavir and Atazanavir

REFERENCES

• Beyrer C. HIV epidemiology update and transmission factors: risks and risk contexts. 16th International AIDS Conference Epidemiology Plenary. Clin Infect Dis. 2007;44:981–987.
   PubMed Web of Science ®Google Scholar
• Chawarski MC, Mazlan M, Schottenfeld RS. Heroin dependence and HIV infection in Malaysia. Drug Alcohol Depend. 2006;82 (Suppl. 1):S39–S42.
   PubMed Web of Science ®Google Scholar
• Surratt HL, Inciardi JA, Weaver JC, Falu VM. Emerging linkages between substance abuse and HIV infection in St. Croix, US Virgin Islands. AIDS Care. 2005;17 (Suppl. 1):S26–S35.
   PubMed Web of Science ®Google Scholar
• Kapadia F, Vlahov D, Donahoe RM, Friedland G. The role of substance abuse in HIV disease progression: reconciling differences from laboratory and epidemiologic investigations. Clin Infect Dis. 2005;41:1027–1034.
   PubMed Web of Science ®Google Scholar
• Sullivan LE, Metzger DS, Fudala PJ, Fiellin DA. Decreasing international HIV transmission: the role of expanding access to opioid agonist therapies for injection drug users. Addiction. 2005;100:150–158.
   PubMed Web of Science ®Google Scholar
• Holmberg SD. The estimated prevalence and incidence of HIV in 96 large US metropolitan areas. Am J Public Health. 1996;86:642–654.
   PubMed Web of Science ®Google Scholar
• Beckson M, Schaefer M. Assessment of HIV risk outcomes in clinical trials for substance abuse pharmacology. NIDA Res Monogr. 1996;162:46–48.
   Google Scholar
• Francis H. Substance abuse and HIV infection. Top HIV Med. 2003;11:20–24.
   PubMedGoogle Scholar
• Royce RA, Sena A, Cates W, Jr, Cohen MS. Sexual transmission of HIV. N Engl J Med. 1997;336:1072–1078.
   PubMed Web of Science ®Google Scholar
• Haubrich RH, Little SJ, Currier JS, , et al. The value of patient-reported adherence to antiretroviral therapy in predicting virologic and immunologic response. California Collaborative Treatment Group. AIDS. 1999;13:1099–1107.
   PubMed Web of Science ®Google Scholar
• Arnsten JH, Demas PA, Grant RW, , et al. Impact of active drug use on antiretroviral therapy adherence and viral suppression in HIV-infected drug users. J Gen Intern Med. 2002;17:377–381.
   PubMed Web of Science ®Google Scholar
• Arici C, Ripamonti D, Maggiolo F, , et al. Factors associated with the failure of HIV-positive persons to return for scheduled medical visits. HIV Clin Trials. 2002;3:52–57.
   PubMedGoogle Scholar
• Tucker JS, Burnam MA, Sherbourne CD, Kung FY, Gifford AL. Substance use and mental health correlates of nonadherence to antiretroviral medications in a sample of patients with human immunodeficiency virus infection. Am J Med. 2003;114:573–580.
   PubMed Web of Science ®Google Scholar
• Gifford AL, Bormann JE, Shively MJ, Wright BC, Richman DD, Bozzette SA. Predictors of self-reported adherence and plasma HIV concentrations in patients on multidrug antiretroviral regimens. J Acquir Immune Defic Syndr. 2000;23:386–395.
   PubMed Web of Science ®Google Scholar
• Lucas GM, Cheever LW, Chaisson RE, Moore RD. Detrimental effects of continued illicit drug use on the treatment of HIV-1 infection. J Acquir Immune Defic Syndr. 2001;27:251–259.
   PubMed Web of Science ®Google Scholar
• Paterson DL, Swindells S, Mohr J, , et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med. 2000;133:21–30.
   PubMed Web of Science ®Google Scholar
• Singh N, Berman SM, Swindells S, , et al. Adherence of human immunodeficiency virus-infected patients to antiretroviral therapy. Clin Infect Dis. 1999;29:824–830.
   PubMed Web of Science ®Google Scholar
• Vlahov D, Galai N, Safaeian M, , et al. Effectiveness of highly active antiretroviral therapy among injection drug users with late-stage human immunodeficiency virus infection. Am J Epidemiol. 2005;161:999–1012.
   PubMed Web of Science ®Google Scholar
• Wang C, Vlahov D, Galai N, , et al. Mortality in HIV-seropositive versus -seronegative persons in the era of highly active antiretroviral therapy: implications for when to initiate therapy. J Infect Dis. 2004;190:1046–1054.
   PubMed Web of Science ®Google Scholar
• Wertheimer BZ, Freedberg KA, Walensky RP, Yazdanapah Y, Losina E. Therapeutic drug monitoring in HIV treatment: a literature review. HIV Clin Trials. 2006;7:59–69.
   PubMed Web of Science ®Google Scholar
• Morse GD, Catanzaro LM, Acosta EP. Clinical pharmacodynamics of HIV-1 protease inhibitors: Use of inhibitory quotients to optimise pharmacotherapy. Lancet Infect Dis. 2006;6:215–225.
   PubMed Web of Science ®Google Scholar
• Bertz RJ, Granneman GR. Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions. Clin Pharmacokinet. 1997;32:210–258.
   PubMed Web of Science ®Google Scholar
• Ray JE, Marriott D, Bloch MT, McLachlan AJ. Therapeutic drug monitoring of atazanavir: surveillance of pharmacotherapy in the clinic. Br J Clin Pharmacol. 2005;60:291–299.
   PubMed Web of Science ®Google Scholar
• Droste JA, Koopmans PP, Hekster YA, Burger DM. TDM: therapeutic drug measuring or therapeutic drug monitoring? Ther Drug Monit. 2005;27:412–416.
   PubMed Web of Science ®Google Scholar
• Boffito M, Acosta E, Burger D, , et al. Therapeutic drug monitoring and drug-drug interactions involving antiretroviral drugs. Antivir Ther. 2005;10:469–477.
   PubMed Web of Science ®Google Scholar
• Molto J, Clotet B. Therapeutic drug monitoring of antiretroviral agents scenario. J HIV Ther. 2004;9:75–78.
   PubMedGoogle Scholar
• Back D, Gatti G, Fletcher C, Garaffo R, Haubrich R, Hoetelmans R, Kurowski M, Luber A, Merry C, Perno C. Therapeutic drug monitoring in HIV infection: current status and future directions. AIDS. 2002;16:S5–S37.
   PubMedGoogle Scholar
• Burger D, Hugen P, Reiss P, , et al. Therapeutic drug monitoring of nelfinavir and indinavir in treatment-naive HIV-1-infected individuals. AIDS. 2003;17:1157–1165.
   PubMed Web of Science ®Google Scholar
• Burger DM, Grintjes KJ, Lotgering FK, Koopmans PP. Therapeutic drug monitoring of nelfinavir in pregnancy: a case report. Ther Drug Monit. 2004;26:576–578.
   Google Scholar
• Burger DM, Hoetelmans RM, Hugen PW, , et al. Low plasma concentrations of indinavir are related to virological treatment failure in HIV-1-infected patients on indinavir-containing triple therapy. Antivir Ther. 1998;3:215–220.
   PubMed Web of Science ®Google Scholar
• Keil K, Frerichs VA, DiFrancesco R, Morse G. Reverse phase high-performance liquid chromatography method for the analysis of amprenavir, efavirenz, indinavir, lopinavir, nelfinavir, and its active metabolite (M8), ritonavir, and saquinavir in heparinized human plasma. Ther Drug Monit. 2003;25:340–346.
   PubMed Web of Science ®Google Scholar
• Holland DT, DiFrancesco R, Connor JD, Morse GD. Quality assurance program for pharmacokinetic assay of antiretrovirals: ACTG proficiency testing for pediatric and adult pharmacology support laboratories, 2003 to 2004: a requirement for therapeutic drug monitoring. Ther Drug Monit. 2006;28:367–374.
   Google Scholar
• Holland DT, DiFrancesco R, Stone J, Hamzeh F, Connor JD, Morse GD. Adult and Pediatric AIDS Clinical Trials Group Pharmacology Laboratory Committees, Pediatric AIDS Clinical Trials Group. Quality assurance program for clinical measurement of antiretrovirals: AIDS clinical trials group proficiency testing program for pediatric and adult pharmacology laboratories. Antimicrob Agents Chemother. 2004;48:824–831.
   PubMed Web of Science ®Google Scholar
• Bond WS, Hussar DA. Detection methods and strategies for improving medication compliance. American Journal of Hospital Pharmacy. 1991;48:1978–1988.
   PubMedGoogle Scholar
• Chesney MA, Ickovics JR, Chambers DB, , et al. Self-reported adherence to antiretroviral medications among participants in HIV clinical trials: the AACTG adherence instruments. Patient Care Committee & Adherence Working Group of the Outcomes Committee of the Adult AIDS Clinical Trials Group (AACTG). AIDS Care. 2000;12:255–266.
   PubMed Web of Science ®Google Scholar
• Gourevitch MN, Friedland GH. Interactions between methadone and medications used to treat HIV infection: a review. Mt Sinai J Med. 2000;67:429–436.
   PubMed Web of Science ®Google Scholar
• Antoniou T, Tseng AL. Interactions between recreational drugs and antiretroviral agents. Ann Pharmacother. 2002;36:1598–1613.
   PubMed Web of Science ®Google Scholar
• Slish JC, Catanzaro LM, Ma Q, Okusanya OO, Demeter L, Albrecht M, Morse GD. Update on the pharmacokinetic aspects of antiretroviral agents: implications in therapeutic drug monitoring. Curr Pharm Des. 2006;12:1129–1145.
   Google Scholar
• Zevin S, Benowitz NL. Drug interactions with tobacco smoking. An update. Clin Pharmacokinet. 1999;36:425–438.
   PubMed Web of Science ®Google Scholar
• Gourevitch MN, Wasserman W, Panero MS, Selwyn PA. Successful adherence to observed prophylaxis and treatment of tuberculosis among drug users in a methadone program. J Addict Dis. 1996;15:93–104.
   PubMed Web of Science ®Google Scholar
• Risk behaviors for HIV transmission among intravenous-drug users not in drug treatment—United States, 1987–1989. MMWR Morb Mortal Wkly Rep. 1990;39:273–276.
   PubMedGoogle Scholar